ENCLAI Daily · Article of the day 30 Sep 2026 · ENCLAI Editorial

Retatrutide 12 mg linked to 18.8% weight loss in adults with obesity and type 2 diabetes

Randomised trialLancet · 29 Sep 2026 · PubMed 42810372

Primary endpointPercentage change from baseline to week 80 in bodyweight for the retatrutide 9 mg and 12 mg doses versus placebo

Retatrutide 4 mg−11.9%
Retatrutide 9 mg−16.8%
Retatrutide 12 mg−18.8%
Placebo−5.1%
Every number here is copied from the published abstract; nothing is estimated. Verify against the paper before use.
Where these numbers come from
“For the treatment regimen estimand, the mean percentage change from baseline in bodyweight at week 80 was -11.9% (SE 0.6) with retatrutide 4 mg, -16.8% (0.7) with retatrutide 9 mg, -18.8% (0.7) with retatrutide 12 mg, and -5.1% (0.7) with placebo.”
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

In a phase 3 trial, adults with obesity and type 2 diabetes who received retatrutide 12 mg once weekly had a mean bodyweight change of -18.8% at week 80, compared with -5.1% for placebo. The authors concluded that retatrutide might be effective for treating obesity in this population.

Who the findings apply to

The trial enrolled adults aged 18 years or older with a BMI of 27 kg/m2 or higher and type 2 diabetes, defined as a glycated haemoglobin (HbA1c) of 6.5% to 10.5%.

Participants were required to be on stable treatment for type 2 diabetes for at least 90 days before screening, which could include diet or exercise alone, or up to three oral glucose-lowering medications.

Eligible participants also needed a history of at least one self-reported unsuccessful dietary effort to reduce bodyweight.

Why this matters

The trial addresses the need for effective weight management in patients with both obesity and type 2 diabetes. The authors state that treatment resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism.

What the study found

At week 80, the mean percentage change from baseline in bodyweight was -11.9% (SE 0.6) with retatrutide 4 mg, -16.8% (0.7) with retatrutide 9 mg, -18.8% (0.7) with retatrutide 12 mg, and -5.1% (0.7) with placebo.

Estimated treatment differences compared with placebo for percentage change in bodyweight were -6.9% (95% CI -8.7 to -5.1) with retatrutide 4 mg, -11.8% (-13.7 to -9.8) with retatrutide 9 mg, and -13.8% (-15.8 to -11.8) with retatrutide 12 mg (p<0.0001 for all).

The authors reported that treatment with retatrutide was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes.

What the result does not establish

Gastrointestinal adverse events were more common in the retatrutide groups than in the placebo group, with diarrhoea occurring in 80 [27%] of 292 participants in the 4 mg group, 95 [34%] of 284 in the 9 mg group, and 96 [34%] of 286 in the 12 mg group vs 38 [13%] of 287 in the placebo group.

Nausea occurred in 40 [14%], 59 [21%], and 80 [28%] vs 23 [8%] in the placebo group.

Permanent treatment discontinuation due to adverse events or death was more frequent in participants treated with retatrutide 9 mg (33 [12%]) and 12 mg (22 [8%]) compared with retatrutide 4 mg (11 [4%]) and placebo (14 [5%]).

The study was funded by Eli Lilly and Company, and the authors note that the results show retatrutide might be effective, rather than definitively proving efficacy.

Authors’ conclusion

“Treatment with retatrutide resulted in substantial improvements in bodyweight and was associated with improvements in glycaemic control in participants with obesity and type 2 diabetes, with a safety profile generally consistent with other molecules with GLP-1 receptor agonism. These results show that retatrutide might be effective for the treatment of obesity in people with type 2 diabetes.”

Trial registration

NCT05929079

Registered titleA Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)
Registry statusPhase 3, interventional, active not recruiting
Lead sponsorEli Lilly and Company
Registered size1,000 participants — planned enrolment (estimate)
Where98 sites in 8 countries (Argentina, Australia, Brazil, India, Mexico, Romania and 2 more)
Registered primary outcomes
  • Percent Change from Baseline in Body Weight (time frame: Baseline, Week 80)
  • Change from Baseline in Apnea-Hypopnea Index (AHI) for GSA2 Subset (time frame: Baseline, Week 80)

Primary endpoint named in the abstract: the percentage change from baseline to week 80 in bodyweight for the retatrutide 9 mg and 12 mg doses versus…. Compare the two: a change of primary endpoint after registration matters.

  • Start: Jul 2023
  • Completion: May 2026 (estimated; this date has passed — check the registry)
  • Primary completion: May 2026 (estimated; this date has passed — check the registry)
  • Paper published: Sep 2026
Filled circle: date reached. Open circle: date the registry lists as estimated.

ClinicalTrials.gov record as held by ENCLAI, last updated Apr 2025. The registry status may have changed since; the link shows the current record.

Study and sources

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial

Randomised trial · Phase 3 · Lancet · 2026-09-29

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.